Stock Price
3.02
Daily Change
0.05 1.68%
Monthly
-3.21%
Yearly
106.85%
Q1 Forecast
2.88

Galectin Therapeutics reported $27.29M in Current Assets for its fiscal quarter ending in June of 2024.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Galectin Therapeutics USD 27.29M 1.83M Jun/2024
Gilead Sciences USD 19.89B 1.05B Dec/2025
Immunic USD 39.27M 20.57M Sep/2025
Incyte USD 5.02B 746.01M Dec/2025
Merck USD 47.56B 10.49B Sep/2025